cease and desist tirzepatide Injections for Medical Weight Loss in Webster TX https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and

During the initial OASIS 4 clinical trial, patients on average lost around 17% of their starting weight, though in a later analysis, early responders (people who'd lost more than 10% of their starting weight by week 16) went on to lose 22% on average by the end of 64 weeks

The SURPASS-2 trial compared tirzepatide with semaglutide 1 mg weekly, showing that tirzepatide achieved HbA1c reductions of 2.01%, 2.24%, and 2.30% at doses of 5 mg, 10 mg, and 15 mg respectively, versus 1.86% with semaglutide

Nauck MA, Wollschlger D, Werner J, et al

They can advise you on any next steps, including how to safely discontinue use

10.2147/CMAR.S188746 78 YanY.WuX.WangP.ZhangS.SunL.ZhaoY.et al (2020)